

**Stroke after TAVR 3**  
**Importance and Methods of  
Neurocognitive Functional Assessments**

***Ronald M. Lazar, PhD, FAHA, FAAN***

***Professor of Neuropsychology***

***Department of Neurology***

***Columbia University Medical Center, NY***

# Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

## Affiliation/Financial Relationship

- Consulting Fees/Honoraria/Advisory Board

## Company

- Claret Medical Inc

# Vascular Cognitive Impairment<sup>1</sup>

**Vascular  
Dementia**



**Vascular Mild  
Cognitive  
Impairment**

**No Stroke**

- Language
- Visual-Spatial Skills




- Attention and Concentration
- Memory
- Executive Function
- Processing Speed

1. Marshall & Lazar, 2011; Gorelick et al, AHA, 2011

# Neurological Adverse Events in Destination LVAD

Brain Regions Assessed by NIH Stroke Scale



## **Impact of Cognitive Impairment**

- ***Difficulty following instructions***
  - ***Unable to comply with a complex medical protocol***
  - ***Unable to provide informed consent for procedures***
  - ***Difficulty in reacting appropriately to a medical emergency***
- 
- **Memory Impairment highly correlated with 30-day re-admission in elderly with CHF (Ketterer, et al, 2014)**
  - **Elevated risk of stroke in older persons with cognitive impairment (Ferrucci et al, 1996)**

# Cardiovascular Disease and Dementia: The Context

## Heart Disease Risk Factors

- Coronary Artery Disease
  - Atrial Fibrillation
  - Myocardia Infarction
  - Heart Failure
  - Valve Disease
- 
- ❑ Left atrial dysfunction increased with mitral disease, contributing to AF, increases risk of dementia<sup>1</sup>
  - ❑ In CHS, those w/o stroke with L sided annular or valvular calcification had 33% greater risk of silent brain infarcts<sup>2</sup>
  - ❑ Autopsy findings: significant aortic/mitral valve damage in individuals with AD<sup>3</sup>

## Rationale for Baseline Neurocognitive and Brain Imaging

1. Boudoulas et al, 2003; 2. Rodriguez et al, 2011; 3. Corder et al, 2005

## Cognitive Trajectory After Transcatheter Aortic Valve Implantation

Ghanem et al, Circ Cardiovasc Interv, 2013

N=111

E1 = Baseline

E2 = 3 Days

E3 = 90 Days


E4 = 1 Yr

E5 = 2 Yrs


Cognitive Task: RBANS (MEAN = 100, SD = 15)

### RESULTS:

- No change in cognition over time
- No association with cerebral embolism on DWI.



# Ghanem et al, 2013




Cognitive Criterion for frank dementia (AD) =  $-2 \text{ SD} < \text{Normative Mean for Age}$




# Does TAVI/TAVR Cause Cognitive Decline from Embolization

(Kahlert et al, Circulation 2010)



(Kahlert et al, Circulation 2010)

Figure 1. Detailed analysis of the MMSE results in TAVI patients.




# Brain magnetic resonance imaging abnormalities in patients with heart failure

Raymond L.C. Vogels<sup>a,b,\*</sup>, Wiesje M. van der Flier<sup>b</sup>, Barbera van Harten<sup>c</sup>, Alida A. Gouw<sup>b</sup>, Philip Scheltens<sup>b</sup>, Jutta M. Schroeder-Tanka<sup>d</sup>, Henry C. Weinstein<sup>a</sup>

*European J Heart Failure, 2007*

## **HF**

- **N = 58**
- **NYHA II, III and IV**
- **Age  $\geq$  50 Yrs old**




Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance

Vogels et al, *Congestive Heart Failure*, 2008


<b><i>Neuropsych Domain</i></b>	<b><i>HF (n=43)</i></b>	<b><i>Cardiac Controls (n=33)</i></b>	<b><i>Healthy Control (n=22)</i></b>	<b><i>P</i></b>
<b><i>MMSE</i></b>	<b><i>27.6 (2.1)</i></b>	<b><i>27.5 (1.97)</i></b>	<b><i>28.1 (1.91)</i></b>	<b><i>.361</i></b>
<b><i>Language</i></b>	<b><i>-0.11 (0.77)</i></b>	<b><i>-0.04 (0.77)</i></b>	<b><i>0.35 (0.71)</i></b>	<b><i>.212</i></b>
<b><i>Visuospatial function</i></b>	<b><i>-0.10 (0.52)</i></b>	<b><i>0.15 (0.37)</i></b>	<b><i>0.25 (0.70)</i></b>	<b><i>.050</i></b>
<b><i>Memory</i></b>	<b><i>-0.23 (0.60)</i></b>	<b><i>0.10 (0.53)</i></b>	<b><i>0.27 (0.93)</i></b>	<b><i>.014</i></b>
<b><i>Executive function</i></b>	<b><i>-0.16 (0.56)</i></b>	<b><i>0.05 (0.54)</i></b>	<b><i>0.33 (0.64)</i></b>	<b><i>.029</i></b>
<b><i>Mental speed/attention</i></b>	<b><i>-0.12 (0.59)</i></b>	<b><i>0.08 (0.52)</i></b>	<b><i>0.24 (0.75)</i></b>	<b><i>.044</i></b>
<b><i>Overall cognitive score</i></b>	<b><i>-0.14 (0.44)</i></b>	<b><i>0.05 (0.38)</i></b>	<b><i>0.29 (0.60)</i></b>	<b><i>.003</i></b>

# The Evolution of the DWI Signal over Time

*Schaefer et al, 2000, Radiology*




2 Hours



## Possible Solutions:

- Pre: DWI (Catheter-related events) and FLAIR (chronic disease)
- 3 – 7 Days after Procedure: DWI
- 30 Days after Procedure: FLAIR

3 Days



## Silent Brain Infarction: *Future Risk* Population-Based Studies

- Presence of silent brain infarcts increases risk of future stroke **2 – 4x** (*Bernick et al, 2001; Vermeer et al, 2003; Vermeer et al, 2007*)
- Stroke risk is highest with silent brain infarction and severe white matter disease (*Kuller et al, 2004*)
- Silent infarcts unmask underlying Alzheimer's disease, especially with new infarcts after baseline (*Vermeer, 2003*)
- Rotterdam Scan Study showed that presence of silent infarction doubled risk of dementia (*Vermeer, 2003*)

## Conclusions

- **The questions regarding neurocognition after TAVR/TAVI remain unanswered.**
- **Neurocognitive batteries need to be comprehensive with good sensitivity and specificity to the underlying pathology.**
- **Imaging should take advantage of the more powerful 3.0 Tesla technology, both for DWI in the acute stage and FLAIR in the chronic period.**
- **Baseline assessments need to take into consideration the impact of the disease before treatment, including brain perfusion.**